Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

In a randomized trial, patients with type 2 diabetes, hypertriglyceridemia, and low HDL cholesterol who received pemafibrate did not have fewer cardiovascular events, although some lipid levels decreased.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-11, Vol.387 (21), p.1923-1934
Hauptverfasser:	Das Pradhan, Aruna, Glynn, Robert J., Fruchart, Jean-Charles, MacFadyen, Jean G., Zaharris, Elaine S., Everett, Brendan M., Campbell, Stuart E., Oshima, Ryu, Amarenco, Pierre, Blom, Dirk J., Brinton, Eliot A., Eckel, Robert H., Elam, Marshall B., Felicio, João S., Ginsberg, Henry N., Goudev, Assen, Ishibashi, Shun, Joseph, Jacob, Kodama, Tatsuhiko, Koenig, Wolfgang, Leiter, Lawrence A., Lorenzatti, Alberto J., Mankovsky, Boris, Marx, Nikolaus, Nordestgaard, Børge G., Páll, Dénes, Ray, Kausik K., Santos, Raul D., Soran, Handrean, Susekov, Andrey, Tendera, Michal, Yokote, Koutaro, Paynter, Nina P., Buring, Julie E., Libby, Peter, Ridker, Paul M
Format:	Artikel
Sprache:	eng
Schlagworte:	Apolipoprotein B Apolipoprotein C-III Apolipoprotein C-III - blood Apolipoproteins Biomarkers Cardiology Cardiology General Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cerebral infarction Cholesterol Cholesterol - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Clinical Medicine Clinical Medicine General Coronary Disease Design Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Disease prevention Double-Blind Method Fatty liver Heart attacks Heart Disease Risk Factors Heart failure High density lipoprotein Hospital-Based Clinical Medicine Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hyperlipidemias - blood Hyperlipidemias - drug therapy Hypertriglyceridemia Hypertriglyceridemia - blood Hypertriglyceridemia - complications Hypertriglyceridemia - drug therapy Hypolipidemic Agents - therapeutic use Ischemia Lipids Lipolysis Lipoproteins Lipoproteins (very low density) Liver diseases Low density lipoprotein Myocardial Infarction Outpatient-Based Clinical Medicine Placebos PPAR alpha - agonists Prevention Research centers Risk Factors Statins Statistical analysis Thromboembolism Triglycerides Triglycerides - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized trial, patients with type 2 diabetes, hypertriglyceridemia, and low HDL cholesterol who received pemafibrate did not have fewer cardiovascular events, although some lipid levels decreased.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2210645